Navigation Links
Tarceva Found To Benefit Older Lung Cancer Patients

A new drug has shown promise in the clinical trials involving lung cancer patients and it has even been proposed to evaluate the drug as a frontline therapy for those with lung cancer. One of the significant problems // faced in the treatment regime in the elderly patients is the tolerability and side effects of the drugs currently used.

The tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer according to researchers from Boston.

Erlotinib is designed to specifically and potently block an overactive growth-signaling molecule (EGFR) in cancer cells. The drug has also showed encouraging activity in patients with failed chemotherapy attempts. The present study is the first reported in the assessment of erlotinib in patients who have not received chemotherapy.

The study involved 80 patients with either Stage IIIB or IV presentation who were subjected to erlotinib treatment for 2 years. Almost 60 percent of the patients experienced either a partial response or had stable disease, though none of them had a complete response. The median survival was 46 weeks, and the median duration of partial response and stable disease was 65 weeks and 24 weeks, respectively.

In addition, all patients were evaluated for survival and toxicity; 69 were evaluated for best response. Ten patients discontinued from the study because of toxicity, and there was one treatment-related death from pneumonitis. Rashes (74%) and diarrhea (60 %) were the most common observed side effects.

Following success of the Phase II trials, the Phase III trial would be directed to comparing erlotinib with single-agent navelbine in the above mentioned population shortly.

In conclusion, erlotinib has been found to display encouraging activity and improve median survival in lung cancer patient s. It is also well tolerated in patients over 70 years, a significant finding.

However, further research might be necessary before the drug can be used in the initial treatment of advanced lung cancer rather than approach involving conventional chemotherapy.
'"/>




Related medicine news :

1. Drug Tarceva for End-stage Lung cancer
2. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
3. Fluoride Found Effective in Osteoporosis
4. Implantable Contact Lens Found Safe and Effective
5. Cancer hazard Found With Animal-Based Nutrients
6. Processed Meat, Diabetes connection Found
7. Night Time Aspirin Regimen Found to Reduce Blood Pressure
8. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
9. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
10. Preventive Therapies Found to be More Effective in Managing Migraines
11. Common Cold Found to Fight Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: